Search Results - "Van Den Bent, M."

Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas by van den Bent, MJ, Prof, Wefel, JS, PhD, Schiff, D, MD, Taphoorn, MJB, Prof, Jaeckle, K, MD, Junck, L, MD, Armstrong, T, PhD, Choucair, A, MD, Waldman, AD, PhD, Gorlia, T, MSc, Chamberlain, M, MD, Baumert, BG, MD, Vogelbaum, MA, MD, Macdonald, DR, MD, Reardon, DA, MD, Wen, PY, Prof, Chang, SM, Prof, Jacobs, AH, Prof

“…Summary Although low-grade gliomas (LGG) have a less aggressive course than do high-grade gliomas, the outcome of these tumours is ultimately fatal in most…”
Get full text

Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial by van den Bent, MJ, Afra, D, de Witte, O, Hassel, M Ben, Schraub, S, Hoang-Xuan, K, Malmström, P-O, Collette, L, Piérart, M, Mirimanoff, R, Karim, ABMF

“…Postoperative policies of “wait-and-see” and radiotherapy for low-grade glioma are poorly defined. A trial in the mid 1980s established the radiation dose. In…”
Get full text

Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma by WELLER, M, GORLIA, T, ROSSETTI, A. O, LACOMBE, D, MIRIMANOFF, R.-O, VECHT, C. J, STUPP, R, CAIRNCROSS, J. G, VAN DEN BENT, M. J, MASON, W, BELANGER, K, BRANDES, A. A, BOGDAHN, U, MACDONALD, D. R, FORSYTH, P

“…This analysis was performed to assess whether antiepileptic drugs (AEDs) modulate the effectiveness of temozolomide radiochemotherapy in patients with newly…”
Get full text

CSF flow cytometry greatly improves diagnostic accuracy in CNS hematologic malignancies by BROMBERG, J. E. C, BREEMS, D. A, KRAAN, J, BIKKER, G, VAN DER HOLT, B, SMITT, P. Sillevis, VAN DEN BENT, M. J, VAN'T VEER, M, GRATAMA, J. W

“…To assess the diagnostic accuracy of flow cytometric immunophenotyping in comparison with classic cytomorphology for diagnosing CNS localizations of…”
Get full text

Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression by DE WIT, M. C. Y, DE BRUIN, H. G, EIJKENBOOM, W, SILLEVIS SMITT, P. A. E, VAN DEN BENT, M. J

“…To determine the frequency of progressive MRI lesions shortly after radiotherapy for glioma with spontaneous improvement or stabilization, the authors studied…”
Get full text

IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide by DUBBINK, H. J, TAAL, W, BOOGERD, W, GROENENDIJK, F. H, SILLEVIS SMITT, PA. E, DINJENS, W. N. M, VAN DEN BENT, M. J, VAN MARION, R, KROS, J. M, VAN HEUVEL, I, BROMBERG, J. E, ZONNENBERG, B. A, ZONNENBERG, C. B. L, POSTMA, T. J, GIJTENBEEK, J. M. M

“…Mutations in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) have been implicated in tumorigenesis of gliomas. Patients with high-grade astrocytomas with IDH1…”
Get full text

Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial by Gao, Y., Weenink, B., van den Bent, M.J., Erdem-Eraslan, L., Kros, J.M., Sillevis Smitt, PAE, Hoang-Xuan, K., Brandes, A.A., Vos, M., Dhermain, F., Enting, R., Ryan, G.F., Chinot, O., Ben Hassel, M., van Linde, M.E., Mason, W.P., Gijtenbeek, J.M.M., Balana, C., von Deimling, A., Gorlia, Th, Stupp, R., Hegi, M.E., Baumert, B.G., French, P.J.

“…The European Organisation for Research and Treatment of Cancer (EORTC) 22033-26033 clinical trial (NCT00182819) investigated whether initial temozolomide (TMZ)…”
Get full text

Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients by DE JONGH, F. E, VAN VEEN, R. N, VELTMAN, S. J, DE WIT, R, VAN DER BURG, M. E. L, VAN DEN BENT, M. J, PLANTING, Asth, GRAVELAND, W. J, STOTER, G, VERWEIJ, J

“…In the present study we describe the toxicity of weekly high-dose (70-85 mg x m(-2)) cisplatin in 400 patients (203 men, 197 women; median age 54 years) with…”
Get full text

Cognitive status and quality of life after treatment for primary CNS lymphoma by HARDER, H, HOLTEL, H, BROMBERG, J. E. C, POORTMANS, P, HAAXMA-REICHE, H, KLUIN-NELEMANS, H. C, MENTEN, J, VAN DEN BENT, M. J

“…To evaluate the cognitive status and quality of life (QOL) in a cohort of 19 consecutive patients treated in a prospective European Organization for Research…”
Get full text

The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study by Boogerd, W., van den Bent, M.J., Koehler, P.J., Heimans, J.J., van der Sande, J.J., Aaronson, N.K., Hart, A.A.M., Benraadt, J., Vecht, Ch.J.

“…To assess the benefit of intraventricular chemotherapy, patients with leptomeningeal metastasis (LM) from breast cancer were randomised to treatment including…”
Get full text

Phase II Study of First-Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971 by VAN DEN BENT, M. J, TAPHOORN, M. J. B, ALLGEIER, A, GORLIA, T, BRANDES, A. A, MENTEN, J, STUPP, R, FRENAY, M, CHINOT, O, KROS, J. M, VAN DER RIJT, C. C. D, VECHT, Ch. J

“…Oligodendroglial tumors are chemotherapy-sensitive tumors, with two thirds of patients responding to combination chemotherapy with procarbazine, lomustine, and…”
Get full text

The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group study by MAILER, M, STUPP, R, MIRIMANOFF, R. O, FORSYTH, P, VAN DEN BENT, M. J, WELLER, M, BOTTOMLEY, A, TAPHOORN, M. J. B, COENS, C, OSOBA, D, MAROSI, C, WONG, R, DE WITTE, O, CAIRNCROSS, J. G, EFFICACE, F

“…This is one of the few studies that have explored the value of baseline symptoms and health-related quality of life (HRQOL) in predicting survival in brain…”
Get full text

The CASPR2 cell adhesion molecule functions as a tumor suppressor gene in glioma by Bralten, L B C, Gravendeel, A M, Kloosterhof, N K, Sacchetti, A, Vrijenhoek, T, Veltman, J A, van den Bent, M J, Kros, J M, Hoogenraad, C C, Sillevis Smitt, P A E, French, P J

“…Genomic translocations have been implicated in cancer. In this study, we performed a screen for genetic translocations in gliomas based on exon-level…”
Get full text

Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas by TRIEBELS, V. H. J. M, TAPHOORN, M. J. B, VAN HEUVEL, I, VAN DEN BENT, M. J, BRANDES, A. A, MENTEN, J, FRENAY, M, TOSONI, A, KROS, J. M, BIEMOND-TER STEGE, E, ENTING, R. H, ALLGEIER, A

“…The authors investigated the results of PCV chemotherapy within a cohort of 24 patients treated within the EORTC study 26971 on temozolomide chemotherapy in…”
Get full text

Frequently asked questions in the medical management of high-grade glioma: a short guide with practical answers by Stupp, R., Hottinger, A. F., van den Bent, M. J., Dietrich, P. -Y., Brandes, A. A.

Get full text

Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972 by van den Bent, M. J., Chinot, O., Boogerd, W., Bravo Marques, J., Taphoorn, M. J. B., Kros, J. M., van der Rijt, C. C. D., Vecht, C. J., De Beule, N., Baron, B.

“…Background: Oligodendroglial tumors are chemosensitive, with two-thirds of patients responding to PCV combination chemotherapy with procarbazine, lomustine…”
Get full text

Pattern of failure in IDH mutated, low grade glioma after radiotherapy – Implications for margin reduction by Jaspers, J.P.M., Méndez Romero, A., Wiggenraad, R., Compter, I., Eekers, D.B.P., Nout, R.A., van den Bent, M.

“…[Display omitted] •The pattern of failure for IDH mutated, grade 2 glioma is predominantly in – field.•Pattern of failure in this study is comparable to…”
Get full text

Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients by Maringwa, J., Quinten, C., King, M., Ringash, J., Osoba, D., Coens, C., Martinelli, F., Reeve, B.B., Gotay, C., Greimel, E., Flechtner, H., Cleeland, C.S., Schmucker-Von Koch, J., Weis, J., Van Den Bent, M.J., Stupp, R., Taphoorn, M.J., Bottomley, A.

“…We aimed to determine the smallest changes in health-related quality of life (HRQoL) scores in the European Organisation for Research and Treatment of Cancer…”
Get full text

Medulloblastoma in adults: evaluation of the Dutch society for neuro-oncology treatment protocol by Bleeker, L., Kouwenhoven, M. C. M., de Heer, I., Lissenberg-Witte, B. I., Gijsbers, A. H., Dubbink, H. J., Kros, J. M., Gijtenbeek, J. M. M., Kurt, E., van der Rijt, C. C. D., Swaak-Kragten, A. T., de Vos, F. Y., van der Weide, H. L., French, P. J., van den Bent, M. J., Wesseling, P., Bromberg, J. E. C.

“…Purpose Medulloblastoma is a rare tumor in adults. The objective of this nationwide, multicenter study was to evaluate the toxicity and efficacy of the Dutch…”
Get full text

Withdrawal of antiepileptic drugs in patients with low grade and anaplastic glioma after long-term seizure freedom: a prospective observational study by Kerkhof, M., Koekkoek, J. A. F., Vos, M. J., van den Bent, M. J., Taal, W., Postma, T. J., Bromberg, J. E. C., Kouwenhoven, M. C. M., Dirven, L., Reijneveld, J. C., Taphoorn, M. J. B.

“…Background When glioma patients experience long-term seizure freedom the question arises whether antiepileptic drugs (AEDs) should be continued. As no…”
Get full text